SYNACT PHARMA ABSYNACT PHARMA ABSYNACT PHARMA AB

SYNACT PHARMA AB

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪405.83 M‬SEK
−4.210SEK
‪−215.81 M‬SEK
0.00SEK
‪28.29 M‬
Beta (1Y)
0.48
Employees (FY)
5
Change (1Y)
0
Revenue / Employee (1Y)
0.00SEK
Net income / Employee (1Y)
‪−43.16 M‬SEK

About SYNACT PHARMA AB


CEO
Jeppe Øvli Øvlesen
Headquarters
Lund
Founded
2016
ISIN
SE0008241491
FIGI
BBG00CZP0DV6
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. It also performs clinical development in order to secure proof-of-concept such as clinical relevance. The company was founded by Søren Nielsen on April 12, 2016 and is headquartered in Lund, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SYNACT is 9.195 SEK — it has decreased by −1.24% in the past 24 hours. Watch SYNACT PHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange SYNACT PHARMA AB stocks are traded under the ticker SYNACT.
SYNACT stock has fallen by −15.65% compared to the previous week, the month change is a 6.65% rise, over the last year SYNACT PHARMA AB has showed a 22.09% increase.
We've gathered analysts' opinions on SYNACT PHARMA AB future price: according to them, SYNACT price has a max estimate of 16.85 SEK and a min estimate of 15.86 SEK. Watch SYNACT chart and read a more detailed SYNACT PHARMA AB stock forecast: see what analysts think of SYNACT PHARMA AB and suggest that you do with its stocks.
SYNACT reached its all-time high on Sep 1, 2023 with the price of 124.600 SEK, and its all-time low was 4.975 SEK and was reached on Mar 11, 2024. View more price dynamics on SYNACT chart.
See other stocks reaching their highest and lowest prices.
SYNACT stock is 2.93% volatile and has beta coefficient of 0.48. Track SYNACT PHARMA AB stock price on the chart and check out the list of the most volatile stocks — is SYNACT PHARMA AB there?
Today SYNACT PHARMA AB has the market capitalization of ‪400.82 M‬, it has decreased by −3.87% over the last week.
Yes, you can track SYNACT PHARMA AB financials in yearly and quarterly reports right on TradingView.
SYNACT PHARMA AB is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
SYNACT net income for the last quarter is ‪−20.49 M‬ SEK, while the quarter before that showed ‪−18.63 M‬ SEK of net income which accounts for −9.99% change. Track more SYNACT PHARMA AB financial stats to get the full picture.
No, SYNACT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 5.00 employees. See our rating of the largest employees — is SYNACT PHARMA AB on this list?
Like other stocks, SYNACT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYNACT PHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYNACT PHARMA AB technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYNACT PHARMA AB stock shows the sell signal. See more of SYNACT PHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.